Evidence map›Paper›PMID 34666434›Full record

ArticleThe Korean journal of internal medicine2021

The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma.

Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ka-Won KangDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Byung-Hyun LeeDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Min Ji JeonDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Eun Sang YuDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Dae Sik KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Se Ryeon LeeDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Hwa Jung SungDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Chul Won ChoiDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Yong ParkDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Byung Soo KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Funding

Korea Health Industry Development InstituteKorea Infectious Diseases Clinical Trials InitiativeMinistry of Health and Welfare HE21C0001
6 · The paper itself

Abstract

BACKGROUND/

aimsRelatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment outcomes in this patient population.

methodsWe retrospectively analyzed data on patients treated for lymphoma or multiple myeloma in two tertiary hospitals in Seoul. Patients were divided into two groups: group 1 included patients who received chemotherapy between September and December 2019 (the control period), and group 2 included patients who received chemotherapy between September and December 2020 (the study period). Countermeasures to COVID-19 were applied to the patients in group 2. The countermeasures implemented included mask wearing and regular handwashing at home and in hospital; COVID-19 risk assessments on all hospital visitors; and pre-emptive COVID-19 screening for all newly hospitalized patients and their resident guardians.

resultsNo differences in treatment outcomes, including treatment response, incidence and duration of neutropenia or neutropenic fever, delays in chemotherapy, or number of deaths during chemotherapy, were observed between the g roups. None of the patients in group 2 tested positive for COVID-19, and there were no COVID-19-related deaths during the study period.

conclusionCountermeasures to COVID-19 did not affect treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. Data on the effect of countermeasures to COVID-19 on treatment outcomes should continue to be analyzed to ensure that treatment outcomes are not adversely affected.

Indexed as

COVID-19LymphomaMultiple MyelomaHumansPandemicsRetrospective StudiesSARS-CoV-2Treatment OutcomeCoronavirusLymphomaMultiple myelomaTreatment outcome

Identifiers

PMID34666434
PMCPMC8588990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.